- Home
- NXTC vs ARTW Comparison
NXTC vs ARTW Comparison
Compare NXTC & ARTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ARTW
- Stock Information
- Founded
- NXTC 2015
- ARTW 1956
- Country
- NXTC United States
- ARTW United States
- Employees
- NXTC N/A
- ARTW 90
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ARTW Industrial Machinery/Components
- Sector
- NXTC Health Care
- ARTW Industrials
- Exchange
- NXTC Nasdaq
- ARTW Nasdaq
- Market Cap
- NXTC 13.9M
- ARTW 9.3M
- IPO Year
- NXTC 2019
- ARTW N/A
- Fundamental
- Price
- NXTC $0.49
- ARTW $1.80
- Analyst Decision
- NXTC Strong Buy
- ARTW
- Analyst Count
- NXTC 2
- ARTW 0
- Target Price
- NXTC $3.50
- ARTW N/A
- AVG Volume (30 Days)
- NXTC 141.9K
- ARTW 15.5K
- Earning Date
- NXTC 05-01-2025
- ARTW 07-02-2025
- Dividend Yield
- NXTC N/A
- ARTW N/A
- EPS Growth
- NXTC N/A
- ARTW N/A
- EPS
- NXTC N/A
- ARTW 0.14
- Revenue
- NXTC N/A
- ARTW $23,916,932.00
- Revenue This Year
- NXTC N/A
- ARTW N/A
- Revenue Next Year
- NXTC N/A
- ARTW N/A
- P/E Ratio
- NXTC N/A
- ARTW $36.40
- Revenue Growth
- NXTC N/A
- ARTW N/A
- 52 Week Low
- NXTC $0.22
- ARTW $1.33
- 52 Week High
- NXTC $1.82
- ARTW $4.15
- Technical
- Relative Strength Index (RSI)
- NXTC 55.20
- ARTW 51.51
- Support Level
- NXTC $0.45
- ARTW $1.73
- Resistance Level
- NXTC $0.52
- ARTW $2.01
- Average True Range (ATR)
- NXTC 0.05
- ARTW 0.10
- MACD
- NXTC 0.01
- ARTW -0.01
- Stochastic Oscillator
- NXTC 66.47
- ARTW 30.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.